Sweta Prajapati
Research Subjects
Research Interests
Sweta Prajapati has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Chehrazi-Raffle
Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA
1 shared publication - Elyse Chan
Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
1 shared publication - Neal Chawla
Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
1 shared publication - Nicolas Sayegh
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX
1 shared publication - Sumanta Kumar Pal
City of Hope Comprehensive Cancer Center, City of Hope, Duarte, CA 91010, USA
1 shared publication
Latest Publications
- Open Access
An Update on the Treatment of Papillary Renal Cell Carcinoma
Papillary renal cell carcinoma (pRCC) is the second-most common subtype of kidney cancer following clear cell renal cell carcinoma (ccRCC), representing 15% of kidney cancers. Despite advances in therapy, including combination strategies with targeted therapies and immune checkpoint inhibitors, progress has lagged behind that of ccRCC. This is in part due to the heterogenous nature of the various subtypes of pRCC. More recently, investigators have turned efforts towards histology and biology-based trials. In this review, we outline some of the distinct biological characteristics of pRCC and discuss the most impactful clinical trials to date. Finally, we look ahead to several highly anticipated ongoing trials in pRCC.
Open AccessAn Update on the Treatment of Papillary Renal Cell Carcinoma
Papillary renal cell carcinoma (pRCC) is the second-most common subtype of kidney cancer following clear cell renal cell carcinoma (ccRCC), representing 15% of kidney cancers. Despite advances in therapy, including combination strategies with targeted therapies and immune checkpoint inhibitors, progress has lagged behind that of ccRCC. This is in part due to the heterogenous nature of the various subtypes of pRCC. More recently, investigators have turned efforts towards histology and biology-based trials. In this review, we outline some of the distinct biological characteristics of pRCC and discuss the most impactful clinical trials to date. Finally, we look ahead to several highly anticipated ongoing trials in pRCC.